Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | ACLY | P53396 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14612820 | 0.87 | ALDH1A1 (0.67) | ALDH1A1LMNAPTBP1KMT2APKM | |
| SCHEMBL35539 | 0.86 | CA1 (0.66) | LMNAPTBP1KMT2AMAPTTDP1 | |
| SCHEMBL30147625 | 0.86 | CA1 (0.66) | LMNAPTBP1KMT2AMAPTTDP1 | |
| SCHEMBL2854385 | 0.84 | LMNA (0.56) | ALDH1A1LMNAPTBP1KMT2AMAPT | |
| SCHEMBL12060827 | 0.84 | LMNA (0.63) | ALDH1A1LMNAPTBP1KMT2APKM | |
| SCHEMBL15629008 | 0.84 | ALDH1A1 (0.63) | ALDH1A1LMNAKMT2APKMSMN1; SMN2 | |
| SCHEMBL3476507 | 0.83 | TDP1 (0.60) | ALDH1A1LMNAPTBP1KMT2APKM | |
| SCHEMBL13545218 | 0.81 | TDP1 (0.55) | ALDH1A1LMNAPTBP1KMT2APKM | |
| SCHEMBL22836941 | 0.81 | LMNA (0.53) | ALDH1A1LMNAPTBP1KMT2APKM | |
| SCHEMBL13543248 | 0.81 | LMNA (0.53) | ALDH1A1LMNAPTBP1KMT2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220048889-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-02-17 | — | — | US | disclosed |
| WO-2020114947-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-06-11 | — | — | WO | disclosed |
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
| EP-2397479-A1 | HETERO RING DERIVATIVE | Astellas Pharma Inc. (JP) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010092962-A1 | HETERO RING DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-08-19 | — | — | WO | disclosed |
| WO-2009111260-A1 | PHENYLSULFONAMIDE-SUBSTITUTED, PYRAZOLO[1, 5-A]PYRIMIDINES, METHODS FOR PREPARATION AND USES THEREOF | WYETH (US) | 2009-09-11 | — | — | WO | disclosed |
| EP-0882707-B1 | NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME | ASAHI CHEMICAL IND (JP) | 2003-10-08 | — | — | EP | disclosed |
| US-20030139475-A1 | Novel tricyclic compounds and drug compositions containing same | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2003-07-24 | — | — | US | disclosed |
| US-6545053-B1 | Aminoethoxyfluorene derivatives are beta-3 adrenaline receptor agonists and are useful as drugs for the treatment and prevention of diabetes, obesity, hyperlipemia, etc. | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2003-04-08 | — | — | US | disclosed |
| US-6187809-B1 | BETA-3 ADRENALINE RECEPTOR AGONIST DRUGS FOR THE TREATMENT OF DIABETES, OBESITY, AND HYPERLIPEMIA; 2-(N-(2-(DIBENZOFURAN-3-YLOXY)ETHYL)AMINO)-1-PHENYLETHANOL, FOR EXAMPLE | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2001-02-13 | — | — | US | disclosed |
| US-6172099-B1 | CARBAZOLE, DIBENZOFURAN, OR DIBENZOTHIOPHENE DERIVATIVES; DIETETICS, ANTIDIABETIC AGENTS; ANTILIPEMICS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2001-01-09 | — | — | US | disclosed |
| EP-0997458-A1 | NOVEL TRICYCLIC COMPOUNDS HAVING SATURATED RINGS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 2000-05-03 | — | — | EP | disclosed |
| US-6037362-A | CARBAZOLE DERIVATIVES; DEPROTECTING, AMINATION; ANTILIPEMIC AND ANTIDIABETIC AGENTS; B-ADRENALINE RECEPTOR AGONISTS; DIETETICS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2000-03-14 | — | — | US | disclosed |
| EP-0882707-A1 | NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1998-12-09 | — | — | EP | disclosed |
| US-5459131-A | Renin inhibitors | AMERICAN CYANAMID COMPANY (US) | 1995-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139475-A1 | Novel tricyclic compounds and drug compositions containing same | ADRB3, MC2R, NR3C1 | ALDH1A1 1815/4885LMNA 3391/4885PTBP1 4824/4885 |
| US-20120165309-A1 | HETERO RING DERIVATIVE | IL2, PIK3R2, IL2RA | ALDH1A1 3496/4885LMNA 4381/4885PTBP1 2120/4885 |
| US-20220048889-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | VHL, FANCI, PAH | ALDH1A1 543/4885LMNA 2437/4885PTBP1 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.